The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 4)
The Daily Biotech Pulse: Pfizer’s Positive Readout, NRx Strikes R&D Collaboration With Mannkind, Cerus & Invitae Jump On Earnings
Here's a roundup of top developments in the biotech space over the last 24 hours.
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 3)
Goldman Sachs Initiates Coverage On Nautilus Biotechnology with Neutral Rating, Announces Price Target of $10
Goldman Sachs analyst Matthew Sykes initiates coverage on Nautilus Biotechnology (NASDAQ:NAUT) with a Neutral rating and announces Price Target of $10.
The Daily Biotech Pulse: Sanofi Buys Translate Bio In $3.2B Deal, Lilly’s Q2 Earnings Disappoint, Bausch To Spin Off Medical Aesthetics Business
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs Aug. 2)
Stocks That Hit 52-Week Lows On Wednesday
Wednesday's morning session saw 27 companies set new 52-week lows.
The Daily Biotech Pulse: AstraZeneca, Biogen Face Clinical Trial Disappointments, Novavax Studies Coronavirus-Flu Combo Vaccine, Decision Day For Takeda
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech Stocks Hitting 52-week Highs June 14)
Last Week’s Notable Insider Buys: Lululemon Athletica, Opendoor Technologies And More
Insider buying can be an encouraging signal for potential investors, especially when markets are near all-time highs.
A SPAC, a REIT and some tech companies saw notable insider buying this past week.
Chief executive officers were among last week's insiders adding to their stakes as well.